Drugs and patents in ATC class D10B - ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE

Last updated: June 9, 2026

ecutive summary
ATC D10B (anti-acne preparations for systemic use) is dominated in most major markets by oral isotretinoin products. Patent and exclusivity risk is therefore driven by (1) generics of existing isotretinoin molecules, (2) product-specific reformulation and manufacturing patents for branded formulations, and (3) any remaining method-of-use or dose-regimen IP that can delay Paragraph IV entry. For current market access planning, the highest practical constraint is usually not the active ingredient chemical patent estate, which is largely expired, but remaining Orange Book-listed formulation and process patents tied to specific NDA holders and specific strengths/finishes.

What patents protect ATC D10B (anti-acne preparations for systemic use)?

Short answer: For D10B, the patent estate typically concentrates around isotretinoin oral products: formulation, particle/crystal form, dissolution/bioperformance, manufacturing process, and occasionally method-of-use claims (dose regimens, cumulative dose targets, or patient subgroups). The chemical composition of isotretinoin itself is generally long expired.

Which systemic anti-acne active ingredients anchor D10B patent estates?

Isotretinoin (oral): primary commercial driver for severe acne (and related acne indications by guideline practice).
Other systemic agents (by how regulators classify products into ATC D10B varies by country): some markets use systemic antibiotics, hormonal therapies, or retinoids categorized differently outside the narrow D10B umbrella; the patent dynamics depend on the local ATC mapping and the exact marketing authorization.

Patent categories most likely to matter for systemic acne launches

Formulation and performance patents
- Drug product composition (excipients, film coating types, release modulators).
- Physical form or polymorph/crystal engineering (less common now, but still used for “better absorption” versions).
- Dissolution and bioavailability improvement, often supported by in vitro release and in vivo pharmacokinetic bridges.
Manufacturing process patents
- Granulation methods, blending parameters, milling, and drying.
- Fill-finish and scale-up steps that support “process innovation” for a branded version.
Method-of-use and dosing regimen patents
- Targeted dose titration algorithms.
- Cumulative dosing strategies aimed at relapse reduction.
- Patient stratification claims (pragmatically enforceable where claims map cleanly to prescribing and labeling).
Device-adjacent or adherence-support patents
- Rare for D10B, but sometimes appear as patient support systems, packaging, or administration aids that are not usually Orange Book-listed as drug substance/product patents.

How strong is the patent estate for systemic isotretinoin (ATC D10B)?

Short answer: In most jurisdictions, the “core” isotretinoin molecule IP strength is weak because composition-of-matter protection is largely expired. The practical enforceable strength tends to sit in remaining product-specific formulation or process patents and any active exclusivities tied to branded NDAs.

Where patent strength concentrates

Branded isotretinoin product lines with distinct release profiles or manufacturing routes can retain enforceable exclusivity longer than the molecule.
Orange Book listing density is usually highest for:
- formulation changes by strength,
- product manufacturing changes,
- and specific NDA supplements that created a new exclusivity “anchor” for later barriers.

What makes enforcement more likely in D10B than in fully generic markets

Isotretinoin is tightly regulated and has high adherence and safety scrutiny.
When a brand controls a unique dissolution profile or clinically accepted bioequivalence boundaries, generic entrants may face additional formulation and process redesign constraints.

When does isotretinoin for severe acne lose exclusivity in the US (Orange Book)?

Short answer: Molecule-level exclusivity has ended in the US for years. The remaining timing gates for generic entry are brand-specific NDA and supplement exclusivities plus any Orange Book drug product patents still listed at launch.

What typically drives the last timing gates

New chemical entity exclusivity: expired for isotretinoin.
505(b)(2) exclusivity: applies if any branded “new route/dose/form” NDA exists, but this is product-specific.
Patent-driven “last bar” to generic entry: whichever is latest among:
- expiration of listed drug product patents,
- expiration of listed method-of-use patents,
- and any Orange Book regulatory exclusivities that survive.

How to interpret “last-to-expire” in a D10B context

If the Orange Book for a brand shows multiple patents across drug substance and drug product categories, the last-to-expire often controls the earliest possible non-at-risk launch.
If only drug substance patents are still listed, generic entry risk is usually lower (because drug product redesign can avoid or skirt those claims). In D10B, however, drug product patents are frequently the ones that still matter.

Which patents are listed in the Orange Book for anti-acne systemic products (D10B) and how many exist per brand?

Short answer: Orange Book coverage for systemic acne products tends to be multi-patent estates: multiple product- and process-related patents per NDA and per strength.

Patent-count impact on Paragraph IV strategy

Higher patent counts generally increase:
- the number of Paragraph IV certifications to defend,
- the chance of at least one patent surviving a dismissal,
- and settlement leverage for brand holders.
In isotretinoin, where product-specific performance claims can be durable, “patent density” often correlates with longer litigation calendars.

What formulation patents can delay generics of oral isotretinoin?

Short answer: Formulation patents delay entry when they claim composition, release control, dissolution targets, or physical form attributes that generic products must replicate to obtain approval without triggering infringement.

Formulation patent subclusters

Release profile patents: controlled release or dissolution specification tied to excipients and manufacturing parameters.
Excipients and matrix composition: claims on exact combinations used to obtain consistent plasma exposure.
Strength-specific formulation: distinct compositions for 10 mg, 20 mg, 30 mg, or 40 mg strengths.

How these patents show up in practice

Generic dossiers often focus on proving bioequivalence, but patent infringement questions turn on:
- whether the generic’s composition and process fall inside the claimed ranges,
- whether the claimed dissolution method and acceptance criteria are satisfied in a way that maps to claim limitations,
- and whether a generic can design around without losing bioequivalence.

What method-of-use patents for systemic acne block generic entry?

Short answer: Method-of-use patents block entry when claims map to labeled dosing and are enforceable against actual prescribing behavior, but they are less common than formulation/process patents.

Common method-of-use claim patterns

Specific dose titration schedule (e.g., starting dose, escalation, and holding parameters).
Cumulative dose targets tied to relapse reduction.
“Use for” claims for subtypes or special populations (severe nodulocystic acne, treatment-resistant cases).

Key litigation dynamic

Even if a generic is approved for the same indication, method-of-use infringement analysis depends on:
- whether the patent claims the act of dosing in a way that is practiced,
- and whether the patent owner can obtain evidence of prescribing/dosing in the claimed way.

What Paragraph IV challenges exist for D10B systemic anti-acne products?

Short answer: Paragraph IV filings for isotretinoin generics are primarily aimed at Orange Book patents listed for specific branded isotretinoin products. The most material factor is which patents are targeted: drug product formulation/process vs method-of-use.

How to read Paragraph IV risk in D10B

If the challenger certifies “not infringed” or “invalid” for drug product patents, brand settlement becomes more likely because trial risk is higher when multiple formulation/process patents exist.
If the challenger targets only patents that expire soon, market timing can dominate settlement decisions.

Typical settlement shape (market-wide)

Cash or milestone payments for non-at-risk launch at a negotiated date.
License to launch under certain patent expiration scenarios.
Consent judgments that effectively align launch dates to the latest relevant patent or exclusivity.

What patent litigation and settlements affect systemic anti-acne launches?

Short answer: Litigation for D10B generally centers on oral isotretinoin NDA holders and their Orange Book-listed drug product and process patents. The settlement outcome most often dictates the first commercial generic SKU and the timing of subsequent strength expansions.

Litigation timeline patterns

Filing of patent infringement suit usually triggers a stay (where applicable) tied to Hatch-Waxman procedural posture.
Settlement can end the stay earlier than patent expiration if the parties agree on launch dates.
Even after the first generic launch, remaining strength patents can delay additional SKUs.

What is the FDA regulatory status of systemic anti-acne drugs (D10B)?

Short answer: D10B systemic acne therapies are FDA-regulated prescription drugs, typically with long-established labeling for severe acne. Generic pathways depend on:

ANDA (for chemically identical isotretinoin)
505(b)(2) only for true formulation/route/dose innovations.

Approval pathway implications for exclusivity

ANDA with Paragraph IV certification is the main mechanism for challenging Orange Book patents.
505(b)(2) products can enter with fewer patent linkages depending on how the reference product and listed patents are carved out in the new NDA.

How does isotretinoin compare with other systemic anti-acne options in patent-driven market access?

Short answer: Alternative systemic options that do exist in markets (e.g., antibiotics or hormonal regimens) may face different patent dynamics, but the D10B systemic acne market is typically anchored by isotretinoin where patent estates have largely expired and current barriers are product-specific.

Competitive implication

Where isotretinoin patents have expired, “market share” is driven by:
- price and supply,
- REMS/handling and distribution readiness,
- and bioequivalence and manufacturing reliability.
Where a brand retains formulation/process patents, it can maintain a de facto moat for a period, even if the molecule is generic.

Which companies are most exposed to D10B patent expiration and generic entry risks?

Short answer:

Branded NDA holders for specific isotretinoin formulations are most exposed to generic Paragraph IV wins or settlements shifting launch dates earlier than modeled.
Generic manufacturers that file Paragraph IV certifications face “at-risk” or delayed-launch outcomes depending on infringement rulings and settlement positions.

Exposure mapping (how investors and litigators model it)

Identify:
- the exact branded NDA(s),
- the Orange Book patents listed against each NDA,
- which patents are still in force,
- and whether multiple strengths have separate patent protection.
Model:
- probability of early invalidation,
- expected timeline to final judgment,
- and settlement probability based on patent density and judge-friendly claim interpretations.

What generic entry risks exist for systemic acne isotretinoin products?

Short answer: The highest risks are:

design-around failure on formulation/process claims,
inability to demonstrate bioequivalence while staying outside claim limitations,
and the persistence of method-of-use patents where prescribing evidence can be developed.

Manufacturing/IP barriers that matter

If a claim covers a process parameter range, generic manufacturing changes may be insufficient to avoid infringement while keeping consistent quality.
If a claim covers dissolution targets, formulation changes can create both performance and infringement risks.

How do patent expirations translate into commercial timing for oral isotretinoin?

Short answer: Commercial launch timing depends on the intersection of:

patent expiration dates,
Orange Book regulatory exclusivity windows,
the Hatch-Waxman stay and settlement date, and
ability to scale manufacturing and secure supply.

Practical timing model

Earliest non-at-risk launch = latest expiration among asserted patents (or settlement carve-outs).
Earliest at-risk launch = challenger’s willingness to accept infringement risk, typically when:
- patents look weak or non-infringed,
- or the challenger expects a favorable early claim construction.

Key Takeaways

D10B systemic anti-acne market is largely an isotretinoin story; molecule-level patents are mostly expired.
The actionable barrier is typically remaining Orange Book drug product and process patent coverage for branded isotretinoin NDAs and specific strengths.
Paragraph IV strategy and litigation outcomes are driven by patent density and whether claims target formulation/performance or method-of-use dosing.
Market timing and revenue exposure hinge on “last-to-expire” within each branded NDA’s Orange Book listings and the settlement date that ends the Hatch-Waxman stay.

FAQs

Do isotretinoin generics need to match a branded dissolution profile to avoid patent infringement?
Can a method-of-use patent prevent an ANDA launch even if the ANDA is bioequivalent?
How do separate strength patents affect multi-SKU isotretinoin generic launches?
What drives settlement timing in isotretinoin Paragraph IV cases: patent strength or manufacturing readiness?
When does Orange Book listing classification (drug substance vs drug product vs method of use) most change infringement risk?

References (APA)

FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
FDA. (n.d.). Hatch-Waxman (Drugs@FDA and ANDA patent certification framework). U.S. Food and Drug Administration.
United States Code. (1984). Title 21, Chapter V, Subchapter A, Part 355 (Food, Drug, and Cosmetic Act), including 21 U.S.C. § 355(j). U.S. Government Publishing Office.

Drugs in ATC Class D10B

Subclasses in ATC: D10B - ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE